Clinical Trials Directory

Trials / Unknown

UnknownNCT05816369

Oral Nutritional Supplement Preferences in Patients With Cancer

Taste and Smell Alterations and Oral Nutritional Supplement (ONS) Preferences in Patients With Cancer

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
University of Bergen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Patients diagnosed with cancer have a particularly high risk of developing malnutrition due to the disease itself and due to symptoms of cancer treatments that can affect food intake such as reduced appetite, nausea, fatigue, and alterations in taste and smell. Nutritional treatment is essential in the prevention and treatment of malnutrition. Oral nutritional supplements (ONS) are often recommended to cancer patients who need to increase their nutritional intake and are unable to meet their nutritional requirements by consumption of normal food alone. However, patient compliance with ONS depends on sensory acceptability of such products. Therefore, the objective of this study is to investigate preferences of sensory characteristics of ONS among cancer patients. Additionally, possible associations between taste and smell alterations and dietary intake, malnutrition risk, and quality of life will be investigated. The results from this study will optimize recommendations of ONS in the clinical setting and encourage new efforts among manufacturers in developing acceptable sensory characteristics of ONS to cancer patients. Findings from this study will contribute to improving nutritional treatment for cancer patients.

Conditions

Interventions

TypeNameDescription
OTHERTaste session of five ONS flavorsPatients will taste a small sample (30 mL) of five ONS flavors and report their taste experiences by completing questionnaires of each flavor during the taste session. Participants will also complete a malnutrition risk screening (MST), a three-day food diary, questionnaires of self-reported taste and smell changes (TSS), and quality of life (RAND-36).

Timeline

Start date
2023-04-11
Primary completion
2023-12-30
Completion
2024-09-30
First posted
2023-04-18
Last updated
2023-12-04

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT05816369. Inclusion in this directory is not an endorsement.